Piperazine derivatives for therapeutic use: a patent review (2010-present)

References

• Al-Ghorbani M, Bushra BA, Zabiulla MSV, et al. Piperazine and morpholine: synthetic preview and pharmaceutical applications. J Chem Pharm Res. 2015;7(5):281–301.
   Google Scholar
• Patel RV, Park SW. An evolving role of piperazine moieties in drug design and discovery. Mini Rev Med Chem. 2013;13(11):1579–1601.
   PubMed Web of Science ®Google Scholar
• Lopez-Rodriguez ML, Ayala D, Benhamu B, et al. Arylpiperazine derivatives acting at 5-HT(1A) receptors. Curr Med Chem. 2002;9:443–469.
   PubMed Web of Science ®Google Scholar
• Haupt A, Pohlki F, Drescher K, et al. N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor. WO2010125134 A1. 2010.
   Google Scholar
• Freire TRV, Mannochio DSRE. Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors. WO2012037634 A1. 2012.
   Google Scholar
• Højer A-M, Drewes PG, Kateb J. New compositions of 1-[2-(2,4-dimethyl- phenylsulfanyl)-phenyl]piperazine. WO2011023194 A2. 2011.
   Google Scholar
• Ito N, Sasaki H, Shinohara T, et al. Heterocyclic compounds for treating or preventing disorders caused by reduced neurotransmission of serotonin, norephnephrine or dopamine. WO2012036253 A1. 2012.
   Google Scholar
• Bang-Andersen B, Mork A, Moore N, et al. 1-[2-(2,4-dimethylphenylsulfanyl)- phenyl]piperazine as A compound with combined serotonin reuptake, 5-HT3 And 5- HT1a activity for the treatment of cognitive impairment. US20140248355 A1. 2014.
   Google Scholar
• Rosini M, Bolognesi ML, Giardina D, et al. Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. Curr Top Med Chem. 2007;7:147–162.
   PubMed Web of Science ®Google Scholar
• SosKic V, Joksimovic J. Bioisosteric approach in the design of new dopaminergic/serotonergic ligands. Curr Med Chem. 1998;5:493–512.
   PubMed Web of Science ®Google Scholar
• Shaquiquzzaman M, Verma G, Marella A, et al. Piperazine scaffold: a remarkable tool in generation of diverse pharmacological agents. Eur J Med Chem. 2015;102:487–529.
   PubMed Web of Science ®Google Scholar
• Lacivita E, Leopoldo M, De Giorgio P, et al. Determination of 1-aryl-4- propylpiperazinepKa values: the substituent on aryl modulates basicity. Bioorg Med Chem. 2009;17:1339–1344.
   PubMed Web of Science ®Google Scholar
• Maia Rdo C, Tesch R, Fraga CAM. Phenylpiperazine derivatives: a patent review (2006 - present). Expert Opin Ther Pat. 2012;22(10):1169–1178.
   PubMed Web of Science ®Google Scholar
• WHO [Internet]. Neurological disorders. 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/mental_health/neurology/neurological_disorders_report_web.pdf
   Google Scholar
• WHO [Internet]. Cancer. 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/cancer/en/
   Google Scholar
• WHO [Internet]. Influenza. 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
   Google Scholar
• WHO [Internet]. Hepatitis C. 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• WHO [Internet]. Cardiovascular diseases (CVDs). 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/cardiovascular_diseases/en/
   Google Scholar
• WHO [Internet]. Diabetes programme. 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/diabetes/en/
   Google Scholar
• WHO [Internet]. Tuberculosis. 2016 [cited 2016 Jan 4]. Available from: http://www.who.int/topics/tuberculosis/en/
   Google Scholar
• Zhang Y, Jin C, Zhou R. Preparation of pyrimidinyl piperazine derivatives as selective serotonin reuptake inhibitors for the treatment and prevention of CNS disorders. WO 2015/014256 A1. 2015.
   Google Scholar
• Achanath R, Jose J, Rangaswamy C, et al. Preparation of piperazine derivatives as imaging agents. WO 2013/041682 A1. 2013.
   Google Scholar
• Harvey RJ, Yee BK. Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013;12(11):866–885.
   PubMed Web of Science ®Google Scholar
• Hoenke C, Giovannini R, Lessel U, et al. Piperazine derivatives and the use of thereof as a medicament. WO 2015/055698 A1. 2015.
   Google Scholar
• Jin L, Yang R, Song R, et al. Preparation of novel piperazine derivatives as dopamine D3 receptor ligands. US 2014/0329831 A1. 2014.
   Google Scholar
• Ganesh T, Sun A, Smith SM, et al. Preparation of piperazine derivatives for use as NADPH-oxidase inhibitors. WO 2012/173952 A1. 2012.
   Google Scholar
• Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behavioural Brain Res. 2003;140:1–47.
   PubMed Web of Science ®Google Scholar
• Heimann A, Dahmann G, Grundl M, et al. Preparation of piperazine derivatives for use as mGluR5 receptor positive allosteric modulators. WO 2013/087805 A1. 2013.
   Google Scholar
• Wisnoski DD, Leister WH, O’Brien JA, et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem. 2004;47:5825–5828.
   PubMed Web of Science ®Google Scholar
• Rudolf K, Bischoff D, Dahmann G, et al. Preparation of piperazine derivatives for use as mGluR5 receptor positive allosteric modulators. WO 2013/087806 A1. 2013.
   Google Scholar
• Stangeland EL, Patterson LJ. 1-(2-Phenoxymethylphenyl)piperazine derivatives as serotonin and norepinephrine reuptake inhibitors and their preparation and use for the treatment of diseases. WO 2011/085291 A1. 2011.
   Google Scholar
• Beswick PJ, Campbell A, Cridland AP, et al. Piperazine derivatives used as Cav2.2 Calcium channel modulators. WO 2010/007072 A1 and WO 2010/007073 A1. 2010.
   Google Scholar
• Olson K. Calcium channel antagonists. In: Poisoning & drug overdose. 6th ed. New York (NY): McGraw-Hill Medical; 2011. ISBN 0071668330.
   Google Scholar
• Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol. 2005;70(4):489–499.
   PubMed Web of Science ®Google Scholar
• Heer JP, Cridland AP, Norton D. Piperazine derivatives for blocking Cav2.2 Calcium channels. WO 2011/086377 A1. 2011.
   Google Scholar
• Beswick PJ, Campbell A, Cridland A, et al. Preparation of piperazine derivatives with affinity for N-type voltage-gated calcium channels for the treatmentof pain. WO 2010/102663 A1. 2010.
   Google Scholar
• Kurose N. A compound having TRPV1 antagonistic activity and uses thereof. US 2013/0123239 A1. 2013.
   Google Scholar
• Schou SC, Dack KN, Greve DR, et al. Preparation of novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof. WO 2012/093169A1. 2012.
   Google Scholar
• Palani A, Berlin MY, Aslanian RG, et al. Preparation of pyrrolidine, piperidine and piperazine derivatives useful in treatment and prevention of diseases. WO2010/045303 A2. 2010.
   Google Scholar
• Williams PD, Mccauley JA, Bennett DJ, et al. Preparation of piperazine derivatives as HIV protease inhibitors. WO 2015013835 A1. 2015.
   Google Scholar
• Yeung KS, Farkas ME, Kadow JF, et al. Indole, azaindole and related heterocyclic N-substituted piperazine derivatives and their preparation and use for the treatment of HIV infection. US 8039486 B2. 2011.
   Google Scholar
• Cheng CC, Huang X, Shipps GW Jr. 1, 4-substituted piperazine derivatives and methods of use thereof. WO 2011/087738 A2. 2011.
   Google Scholar
• Sofia MJ, Kakarla R, Liu J, et al. Preparation of piperazine derivatives and their uses to treat viral infections, including hepatitis C. US2012/0202794 A1. 2012.
   Google Scholar
• Cianci CW, Gerritz S, Kim S, et al. Heteroaryl-piperazine derivatives as influenza antivirals and their preparation, pharmaceutical compositions and use in the treatment of viral infection. WO 2012/044531 A1. 2012.
   Google Scholar
• Dessole G, Jones P, Bufi LL, et al. Preparation of 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as SMO antagonists. WO2010/013037 A1. 2010.
   Google Scholar
• Jones P, Maria Ontoria OJ. Preparation of Piperidine and piperazine derivatives as SMO antagonist. WO2011/036478 A1. 2011.
   Google Scholar
• Fajas L, Benfodda Z, Fritz V. Preparation of piperazine derivatives as inhibitors of stearoyl-CoA-desaturase-1 enzyme. WO 2011/030312 A1. 2011.
   Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485–495.
   PubMed Web of Science ®Google Scholar
• Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462.
   PubMed Web of Science ®Google Scholar
• Zhao G, Zhu Y, Eno CO, et al. Activation of the proapoptotic Bcl-2 protein Bax by a small molecule induces tumor cell apoptosis. Mol Cell Biol. 2014;34(7):1198–1207.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhou H, Chen J, et al. BCL-2/BCL-XL inhibitors and therapeutic methods using the same. US 2012/0189539 A1. 2012.
   Google Scholar
• Kohno K, Uchiumi T, Niina I, et al. Transcription factors and drug resistance. Eur J Cancer. 2005;41:2577–2586.
   PubMed Web of Science ®Google Scholar
• Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005;111:127–148.
   PubMedGoogle Scholar
• Carniato D, Briand J-F, Gutmann M, et al. Preparation of piperazine derivatives useful for the treatment of cancers, especially cancers resistant to chemotherapy. WO 2013098393 A1. 2013.
   Google Scholar
• Wang S, Zhou H, Chen J, et al. Synthesis of piperazine derivatives as Bcl-​2​/Bcl-​xL inhibitors. US 20120189539 A1. 2012.
   Google Scholar
• Makiko U-G, Yasuhiro K, Akitsu T, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002;158(2):227–233.
   PubMed Web of Science ®Google Scholar
• Tokumura A, Kanaya Y, Kitahara M, et al. Increased formation of lysophosphatidic acids by lysophospholipase D in serum of hypercholesterolemic rabbits. J Lipid Res. 2002;43(2):307–315.
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–644.
   PubMed Web of Science ®Google Scholar
• Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995;1(10):1223–1232.
   PubMed Web of Science ®Google Scholar
• Schiemann K, Schultz M, Staehle W. Piperidine and piperazine derivatives as autotaxin inhibitors and their preparation and use for the treatment and prophylaxis of cancers and other autotaxin-​mediated diseases. WO 2010115491 A2. 2010.
   Google Scholar
• Buzard DJ, Han S, Jones RM, et al. Piperazine derivatives as GPR119 receptor modulators and their preparation and use for the treatment of GPR119 receptor-​related diseases. WO2012/145361 A1. 2012.
   Google Scholar
• Lan H, Vassileva G, Corona A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol. 2009;201(2):219–230.
   PubMed Web of Science ®Google Scholar
• Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat Rev Drug Discov. 2012;11(8):603–619.
   PubMed Web of Science ®Google Scholar
• Boyle CD, Lankin CM, Shah UG, et al. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders. WO 2010/114957 A1. 2010.
   Google Scholar
• Bi Y, Dzierba CD, Bronson JJ, et al. Modulators of G-protein-coupled receptor 88. WO 2011/044195 A1. 2011.
   Google Scholar
• Kannoji A, Phukan S, Sudher Babu V, et al. GSK3β: a master switch and a promising target. Expert Opin Ther Targets. 2008;12:1443–1455.
   PubMed Web of Science ®Google Scholar
• Imahori K, Uchida T. Physiology and pathology of tau protein kinases in relation to Alzheimer’s disease. J Biochem. 1997;121(2):179–188.
   PubMed Web of Science ®Google Scholar
• Ahlin K, Arvidsson PI, Huerta F, et al. Oxazolo [4,5-C] pyridine substituted pyrazine. WO 2011/059388A1. 2011.
   Google Scholar
• Staehle W, Tsaklakidis C, Friese-Hamim M, et al. Piperazine derivatives as FANS inhibitors. WO 2014/146747 A1. 2014.
   Google Scholar
• Bischoff A, Subramanya H, Sundaresan K, et al. Novel piperazine derivatives as inhibitors of stearoyl-COA desaturase. US 2010/0160323 A1. 2010.
   Google Scholar
• Xiao D, Palani A, Aslanian RG. Piperidine and Piperazine derivatives and methods of use thereof. WO2010/071822 A1. 2010.
   Google Scholar
• Steckelings UM, Kaschina E, Unger T. The AT2 receptor – a matter of love and hate. Peptides. 2005;26(8):1401–1409.
   PubMed Web of Science ®Google Scholar
• Chakrabarty A, Blacklock A, Svojanovsky S, et al. Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology. 2008;149(7):3452–3460.
   PubMed Web of Science ®Google Scholar
• Clere N, Corre I, Faure S, et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer. 2010;127:2279–2291.
   PubMed Web of Science ®Google Scholar
• Izu Y, Mizoguchi F, Kawamata A, et al. Angiotensin II Type 2 receptor blockade increases bone mass. J Biol Chem. 2009;284(8):4857–4864.
   PubMed Web of Science ®Google Scholar
• Mccarthy TD, Naylor A. Heterocyclic compounds and methods for their use. WO2013/110134 A1. 2013.
   Google Scholar
• Ho K, Nichols CG, Lederer WJ, et al. Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature. 1993;362(6415):31–38.
   PubMed Web of Science ®Google Scholar
• Hebert SC, Desir G, Giebisch G, et al. Molecular diversity and regulation of renal potassium channels. Physiol Rev. 2005;85(1):319–371.
   PubMed Web of Science ®Google Scholar
• Pasternak A, Shahripour A, Tang H, et al. Inhibitors of the renal outer medullary potassium channel. WO 2010/129379 A1. 2010.
   Google Scholar
• Walsh SP, Pasternak A, Dejesus RK, et al. Inhibitors of the renal outer medullary potassium channel. WO 2013/066714 A1. 2013.
   Google Scholar
• Schmitt-Willich H, Röhn U, Friebe M, et al. Preparation of isotope-labeled piperazine derivatives for binding and imaging amyloid plaques and their use. WO 2010/028776 A1 and EP 2163 541 A1. 2010.
   Google Scholar
• Schmitt-Willich H, Heinrich T, Brockschnieder D Preparation of piperazine derivatives as PET imaging agents of amyloid plaques. WO 2011/110488 A1. 2011.
   Google Scholar
• Schmitt-Willich H, Heinrich T, Brockschnieder D. Preparation of piperazine derivatives as spect imaging agents of amyloid plaques. WO 2011/110511 A1. 2011.
   Google Scholar
• Newington IM, Wynn DG, Nairne RJD, et al. Piperazine derivatives and radiolabeled analogs as 5HT1A ligands and their preparation and use as imaging agent and in treatment of 5HT1A-​associated diseases. WO 2011/150183 A1. 2011.
   Google Scholar
• Bell IM, Hostetler E, Selnick HG, et al. Radiolabeled piperazine derivatives as CGRP antagonist and their preparation and use for the imaging of CGRP receptors. WO 2011/014383 A1. 2011.
   Google Scholar
• Keliher EJ, Reiner T, Weissleder R. Preparation of substituted piperazine derivatives for use in targeting PARP-​1 for detection and imaging of cancer.WO 2012/074840 A2. 2012.
   Google Scholar
• Csonka I, Grolmusz V, Répási J, et al. Piperazine derivatives and their preparation and use as tuberculostatics. WO 2011/089456 A1. 2011.
   Google Scholar